Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery technology...

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...

Schizophrenia Treatment Advances with Emerging Pipeline Insights Through 2024 Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Schizophrenia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This report confers a rich, panoramic view of...

Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...

Olanzapine Market Report 2024 - Global Trends, Forecasts and Competitive Analysis to 2030 - Opportunities in the Bipolar Disorder and Schizophrenia Markets Dublin, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "Olanzapine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...